Back close

Synthesis, Biological Evaluation and Molecular Docking Studies of Stellatin Derivatives as Cyclooxygenase (COX-1, COX-2) Inhibitors and Anti-inflammatory Agents

Publication Type : Journal Article

Thematic Areas : Nanosciences and Molecular Medicine

Publisher : Bioorganic Medicinal Chemistry Letters

Source : Bioorganic & Medicinal Chemistry Letters, Volume 21, Number 6, p.1612 - 1616 (2011)

Url : http://www.sciencedirect.com/science/article/pii/S0960894X11001508

Keywords : anti-inflammatory, antioxidant, Chromones, Cyclooxygenase (COX)-1 and -2, molecular docking, Stellatin

Campus : Kochi

School : Center for Nanosciences

Center : Amrita Center for Nanosciences and Molecular Medicine Move, Nanosciences

Department : Nanosciences and Molecular Medicine

Year : 2011

Abstract : Stellatin (4), isolated from Dysophylla stellata is a cyclooxygenase (COX) inhibitor. The present study reports the synthesis and biological evaluation of new stellatin derivatives for COX-1, COX-2 inhibitory and anti-inflammatory activities. Eight derivatives showed more pronounced COX-2 inhibition than stellatin and, 17 and 21 exhibited the highest COX-2 inhibition. They also exhibited the significant anti-inflammatory activity in TPA-induced mouse ear edema assay and their anti-inflammatory effects were more than that of stellatin and indomethacin at 0.5mg/ear. The derivatives were further evaluated for antioxidant activity wherein 16 and 17 showed potent free radical scavenging activity against DPPH and ABTS radicals. Molecular docking study revealed the binding orientations of stellatin and its derivatives into the active sites of COX-1 and COX-2 and thereby helps to design the potent inhibitors.

Cite this Research Publication : R. Gautam, Jachak, S. M., Kumar, V., and Dr. Gopi Mohan C., “Synthesis, Biological Evaluation and Molecular Docking Studies of Stellatin Derivatives as Cyclooxygenase (COX-1, COX-2) Inhibitors and Anti-inflammatory Agents”, Bioorganic & Medicinal Chemistry Letters, vol. 21, pp. 1612 - 1616, 2011.

Admissions Apply Now